CN112996790B - 用于调节cdk9活性的化合物、组合物和方法 - Google Patents

用于调节cdk9活性的化合物、组合物和方法 Download PDF

Info

Publication number
CN112996790B
CN112996790B CN201980072853.7A CN201980072853A CN112996790B CN 112996790 B CN112996790 B CN 112996790B CN 201980072853 A CN201980072853 A CN 201980072853A CN 112996790 B CN112996790 B CN 112996790B
Authority
CN
China
Prior art keywords
mmol
pyrimidin
reaction mixture
cdk9
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980072853.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112996790A (zh
Inventor
P·米科奇克
J·瓦卡
D·弗里曼
A·塔斯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cronos Biological Co
Original Assignee
Cronos Biological Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cronos Biological Co filed Critical Cronos Biological Co
Publication of CN112996790A publication Critical patent/CN112996790A/zh
Application granted granted Critical
Publication of CN112996790B publication Critical patent/CN112996790B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980072853.7A 2018-10-30 2019-10-29 用于调节cdk9活性的化合物、组合物和方法 Active CN112996790B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US62/752,635 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US62/884,993 2019-08-09
US201962910058P 2019-10-03 2019-10-03
US62/910,058 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (2)

Publication Number Publication Date
CN112996790A CN112996790A (zh) 2021-06-18
CN112996790B true CN112996790B (zh) 2023-11-03

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072853.7A Active CN112996790B (zh) 2018-10-30 2019-10-29 用于调节cdk9活性的化合物、组合物和方法

Country Status (21)

Country Link
US (3) US11155560B2 (cg-RX-API-DMAC7.html)
EP (2) EP3873911A4 (cg-RX-API-DMAC7.html)
JP (1) JP7385658B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250174699A (cg-RX-API-DMAC7.html)
CN (1) CN112996790B (cg-RX-API-DMAC7.html)
AU (1) AU2019370200B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008176A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118472A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005502A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210202A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000066A (cg-RX-API-DMAC7.html)
IL (1) IL282254B2 (cg-RX-API-DMAC7.html)
MA (1) MA54092A (cg-RX-API-DMAC7.html)
MD (1) MD20210033A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004769A (cg-RX-API-DMAC7.html)
MY (1) MY210039A (cg-RX-API-DMAC7.html)
PE (1) PE20212196A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550857A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104229WA (cg-RX-API-DMAC7.html)
WO (1) WO2020092314A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102609B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250174699A (ko) * 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
WO2022098843A1 (en) * 2020-11-05 2022-05-12 Kronos Bio, Inc. Compounds and methods for modulating cdk9 activity
AU2022211514B2 (en) * 2021-01-22 2024-06-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
EP4436569A4 (en) * 2021-11-24 2025-10-01 Kronos Bio Inc POLYMORPHIC AND SALT FORMS OF (LS,3S))-N-(5-(PENTAN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)CYCLOPENTANE-L,3-DIAMINE
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
WO2024017365A1 (zh) * 2022-07-22 2024-01-25 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用
WO2025153034A1 (zh) * 2024-01-19 2025-07-24 上海海雁医药科技有限公司 一种吡唑并嘧啶衍生物的磷酸盐多晶型物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022561A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
CN101039945A (zh) * 2004-08-13 2007-09-19 帝人制药株式会社 吡唑并[1,5-a]嘧啶衍生物
CN101321756A (zh) * 2005-10-06 2008-12-10 先灵公司 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物
CN101573363A (zh) * 2006-10-04 2009-11-04 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的新颖的吡唑并嘧啶
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2019023654A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology DISCOVERING SMALL MOLECULES TARGETING THE ANDROGEN RECEPTOR AND USES THEREOF

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
EP0714898B1 (en) * 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
PL354675A1 (en) 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd 5−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
WO2003095455A2 (en) 2002-05-10 2003-11-20 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
DE60313872T2 (de) * 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
US20070293511A1 (en) 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
CN101119998A (zh) 2004-12-21 2008-02-06 先灵公司 吡唑并[1,5-A]嘧啶腺苷A2a受体拮抗剂
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
EP1931675B1 (en) 2005-10-06 2015-01-14 Merck Sharp & Dohme Corp. Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2027127A1 (en) 2006-05-22 2009-02-25 Shering Corporation Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors
JP2010529140A (ja) 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
CA2691932A1 (en) 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
WO2010074284A1 (ja) 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
PH12012501643A1 (en) 2010-02-26 2017-07-19 Mitsubishi Tanabe Pharma Corp Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
WO2011108689A1 (ja) 2010-03-05 2011-09-09 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
CN102958933B (zh) 2010-06-24 2016-02-03 吉里德科学公司 作为抗病毒药的吡唑并[1,5-a]嘧啶类
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012044562A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EP2802588B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted pyrazolopyrimidines as akt kinase inhibitors
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
EP2920181B1 (en) 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
SG11201507629XA (en) * 2013-03-15 2015-10-29 Human Biomolecular Res Inst Compounds and matrices for use in bone growth and repair
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2015153732A2 (en) 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
EP3805218A1 (en) 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3268000B1 (en) 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016169995A1 (en) 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
ES2767776T3 (es) 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
WO2017180499A2 (en) 2016-04-13 2017-10-19 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
KR20250174699A (ko) * 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022561A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
CN101039945A (zh) * 2004-08-13 2007-09-19 帝人制药株式会社 吡唑并[1,5-a]嘧啶衍生物
CN101321756A (zh) * 2005-10-06 2008-12-10 先灵公司 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物
CN101573363A (zh) * 2006-10-04 2009-11-04 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的新颖的吡唑并嘧啶
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2019023654A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology DISCOVERING SMALL MOLECULES TARGETING THE ANDROGEN RECEPTOR AND USES THEREOF

Also Published As

Publication number Publication date
KR20210068597A (ko) 2021-06-09
EP4775584A1 (en) 2026-07-15
MX2021004769A (es) 2021-08-24
MA54092A (fr) 2021-09-08
US11155560B2 (en) 2021-10-26
PE20212196A1 (es) 2021-11-16
JP2022505268A (ja) 2022-01-14
US20240132506A1 (en) 2024-04-25
IL282254B2 (en) 2025-08-01
DOP2021000066A (es) 2021-10-31
CA3118472A1 (en) 2020-05-07
CR20210202A (es) 2022-02-08
IL282254B1 (en) 2025-04-01
PH12021550857A1 (en) 2021-12-06
KR20250174699A (ko) 2025-12-12
MY210039A (en) 2025-08-22
US11845754B2 (en) 2023-12-19
IL282254A (en) 2021-05-31
AU2019370200A1 (en) 2021-06-10
CN112996790A (zh) 2021-06-18
EP3873911A4 (en) 2022-06-22
BR112021008176A2 (pt) 2021-08-03
CO2021005502A2 (es) 2021-09-20
WO2020092314A1 (en) 2020-05-07
ZA202102609B (en) 2023-02-22
AU2019370200B2 (en) 2024-12-19
US20220002305A1 (en) 2022-01-06
SG11202104229WA (en) 2021-05-28
EP3873911A1 (en) 2021-09-08
JP7385658B2 (ja) 2023-11-22
US20200131189A1 (en) 2020-04-30
MD20210033A2 (ro) 2021-10-31

Similar Documents

Publication Publication Date Title
US11845754B2 (en) Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
EP3889145B1 (en) 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
KR102396717B1 (ko) Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료
JP7239554B2 (ja) Tlr7/8アンタゴニストおよびそれらの使用
JP2022546520A (ja) Rip1阻害化合物ならびにそれを作製および使用するための方法
US9260435B2 (en) Substituted imidazopyrazines as Akt kinase inhibitors
US12508264B2 (en) Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
JP2020528062A (ja) ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
UA111739C2 (uk) Імідазопіридазини як інгібітори аkt-кінази
US9370517B2 (en) Substituted pyrazolopyrimidines as Akt kinase inhibitors
WO2026015417A1 (en) Inhibitors of protein tyrosine phosphatase, compositions, and methods of use
EP3704103A1 (en) Kinase inhibitors for the treatment of central and peripheral nervous system disorders
US8987286B2 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway
AU2022347609A1 (en) Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors
EA043715B1 (ru) Соединения, композиции и способы модуляции активности cdk9
JP7354246B2 (ja) ピロロピリミジン骨格を有する新規なリン酸エステル化合物又はその薬学的に許容可能な塩
OA20540A (en) Compounds, compositions, and methods for modulating CDK9 activity.
RU2514937C2 (ru) Дигидропиридофталазиноновые ингибиторы поли(адф-рибоза)полимеразы
CN120040418A (zh) 一类含有单环芳基取代的cdk12/13的降解剂,及其制备方法、药物组合物和应用
HK1185881B (en) Substituted imidazo[1,2-b]pyridazines
NZ620421B2 (en) Tenofovir alafenamide hemifumarate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant